| [1] | KIVIMÄKI M, STRANDBERG T, PENTTI J, et al. Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study[J]. Lancet Diabetes Endocrinol, 2022, 10(4):253-263. doi: 10.1016/S2213-8587(22)00033-X |
| [2] | World Obesity Federation, World Obesity Atlas 2023[EB/OL]. (2023-03) [2023-08]. https://data.worldobesity.org/publications/?cat=19. |
| [3] | CHEN K, SHEN Z W, GU W J, et al. Prevalence of obesity and associated complications in China: a cross-sectional, real-world study in 15.8 million adults[J]. Diabetes Obes Metab, 2023, 25(11):3390-3399. doi: 10.1111/dom.15238 |
| [4] | 国家药品监督管理局, 2023年07月04日药品批准证明文件送达信息发布[EB/OL]. (2023/07/04) [2023-08]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20230704155106142.html. |
| [5] | GRUNVALD E, SHAH R, HERNAEZ R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity[J]. Gastroenterology, 2022, 163(5):1198-1225. doi: 10.1053/j.gastro.2022.08.045 |
| [6] | SHI Q Y, WANG Y, HAO Q K, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials[J]. Lancet, 2022, 399(10321):259-269. doi: 10.1016/S0140-6736(21)01640-8 |
| [7] | BULIK C M, HARDAWAY J A. Turning the tide on obesity?[J]. Science, 2023, 381(6657):463. doi: 10.1126/science.adj9953 |
| [8] | PRILLAMAN M. Four key questions on the new wave of anti-obesity drugs[J]. Nature, 2023, 620(7972):28-30. doi: 10.1038/d41586-023-02445-4 |
| [9] | SUN Y, YANG Y L, QIN Z, et al. The acute-phase protein orosomucoid regulates food intake and energy homeostasis via leptin receptor signaling pathway[J]. Diabetes, 2016, 65(6):1630-1641. doi: 10.2337/db15-1193 |
| [10] | European Medicines Agency, ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals[S/OL]. 2013, https://www.ema.europa.eu/en/ich-m3-r2-non-clinical-safety-studies-conduct-human-clinical-trials-pharmaceuticals-scientific#current-effective-version-section. |
| [11] | 食品药品监管总局, 药物遗传毒性研究技术指导原则[EB/OL]. (2018.03.15) [2023-08]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20180315160901208.html. |
| [12] | FAQI A S. Introduction[M]. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. Amsterdam: Elsevier, 2017: 1-4. |
| [13] | PROUDLOCK R. Genetic Toxicology testing A laboratory manual [M]. Amsterdam: Elsevier, 2013. |